Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ZLAB
ZAI LAB LIMITED
NASDAQ
$26.08
▼ DOWN 2.76% (-0.74)

KEY STATISTICS

Market Cap$2.95 B
52w High$34.72
52w Low$15.96
Dividend Yield—
Frequency—
P/E-15.25
Volume650.03K
Shares Out.112.92M

COMPANY

LEADERSHIP

Ying Du
CHIEF EXECUTIVE
Ying Du

COMPENSATION 2026

Salary$908,730
Stock Awards$3,233,729
Incentive Plan Pay$695,178
All Other Comp.$17,500
Total$10,677,221

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 20, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,784

PRICE TARGET

Target High$75.00
Target Low$35.00
Target Median$52.50
Target Consensus$53.75

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$108.83M
NOV
5
THU

PRICE

$26.08 ▼ DOWN 2.76% (−$0.74)
$25.95$26.10$26.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM26.08

About Zai Lab Limited

https://www.zailaboratory.com ↗

Zai Lab Limited, founded in 2013 in Shanghai, develops and commercializes innovative therapies across oncology, autoimmune, infectious, and neurological diseases mainly in China and Hong Kong, with a diverse pipeline of drugs and devices.

INDUSTRY

Biotechnology

A PRODUCT ZAI LAB LIMITED IS KNOWN FOR

COBENFY (xanomeline and trospium chloride)
COBENFY (xanomeline and trospium chloride)

COBENFY is a first-in-class oral schizophrenia treatment approved in China in December 2025, offering a novel mechanism by selectively activating brain muscarinic receptors to address unmet needs of 8 million affected adults.

COMPETITORS

COMPETITOR
ABBV COMPARE
ACAD COMPARE
ALKS COMPARE
LLY COMPARE
NBIX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Zejula$42.43M $56.04M ▲$29.97M ▼$32.08M ▲
Nuzyra$15.43M $16M ▲$16.26M ▲$17.1M ▲
Optune$12.66M $11.95M ▼$12.07M ▲$12.2M ▲
Qinlock$8.9M $9.67M ▲$8.98M ▼$9.59M ▲
Product and Service Other$92K $0 ▼$357K ▲$195K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
29
LISTED HERE
18
RANKED BY POSITION SIZE
IBB
0.16% · 670.1K
CANC
1.99% · 161.3K
SBIO
1.45% · 134.3K
BBP
1.93% · 85.8K
DFEM
0.01% · 26.0K
SILX
3.31% · 20.9K
GERM
3.60% · 20.7K
PGJ
0.59% · 20.1K
FMED
0.78% · 15.3K
FNI
0.66% · 12.8K
NS
NSI
0.28% · 4.5K
SPGM
0.01% · 4.0K
BCEM
0.13% · 2.5K
CH
CHNA
1.99% · 2.2K
BIB
0.03% · 1.2K
NTSE
0.02% · 425
EMCR
0.01% · 159
FXCN.ME
0.19% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
34.82%
HOLDERS
205
TOP 12 OF 205 · RANKED BY POSITION SIZE
Rtw Investments, LP
7.0M sh · $122.76M
Capital World Investors
6.1M sh · $205.97M
Ra Capital Management, L.P.
5.7M sh · $107.35M
Fmr LLC
4.7M sh · $159.34M
Clearbridge Investments, LLC
3.5M sh · $119.27M
Janus Henderson Group Plc
2.0M sh · $69.49M
Frazier Life Sciences Management, L.P.
1.9M sh · $33.56M
Ubs Group AG
1.8M sh · $31.44M
Wellington Management Group Llp
1.7M sh · $58.24M
Citadel Advisors LLC
1.7M sh · $31.76M
Bamco Inc /Ny/
1.7M sh · $31.19M
Segantii Capital Management Ltd
1.6M sh · $24.93M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Chen Yajing
Sale · 260 shares
2026-08-19
★
OFFICER: CHIEF FINANCIAL OFFICER
Chen Yajing
Sale · 1.3K shares
2026-08-14
★
OFFICER: CHIEF FINANCIAL OFFICER
Chen Yajing
Purchase · 1.3K shares
2026-08-14
★
OFFICER: CHIEF FINANCIAL OFFICER
Chen Yajing
Sale · 427 shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
BUY 1
3 GRADES IN THE LAST 12 MONTHS
Citigroup BUY JP Morgan OVERWEIGHT Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
SRRK$57.80COMPARE
XENE$59.99COMPARE
IDYA$40.11COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE
AAPG$18.28COMPARE